Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

During the developing COVID-19 pandemic, the Nuffield Department of Medicine Research Building is taking measures to prevent the spread of the disease.

Departments are instructed by the University's Registrar to continue to work from home where possible, and manage the return to on site working, based on the University guidelines for risk assessments and work prioritisation.

This is to restrict contact between individuals as far as possible.  The University remains open and operating as far as possible with the following restrictions:

  • No public access to the University
  • On-site activity permitted where it cannot be undertaken remotely, driven by safety, capacity and other factors such as schools reopening/other changes in government guidelines
  • Teaching and assessment are undertaken remotely where possible and, depending on government guidelines, gatherings of staff and students only permitted where essential for teaching and assessment to take place

LATEST NEWS

Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium

Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Recent publications